Related Experiment Video

Updated: Aug 22, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications

C Akgul1, D A Moulding, S W Edwards

  • 1Faculty of Arts and Sciences, Department of Chemistry, Biochemistry Research Group, Canakkale Onsekiz Mart University, Terzioglu Campus, 17100, Canakkale, Turkey. cahitakgul@comu.edu.tr

Cellular and Molecular Life Sciences : CMLS
|September 1, 2004
PubMed

Insights

Alternative splicing generates Bcl-2 family protein diversity, regulating apoptosis. Manipulating splicing offers therapeutic potential for diseases like cancer by restoring protein balance.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Genetics

Background:

  • Apoptosis, a regulated cell death process, is controlled by Bcl-2 family proteins.
  • Bcl-2 family proteins, with over 20 members and multiple isoforms, critically regulate apoptosis.
  • Alternative splicing is a key mechanism driving Bcl-2 family proteomic complexity and functional diversity.

Purpose of the Study:

  • To review current knowledge on alternative splicing in Bcl-2-related genes.
  • To explore the therapeutic potential of modulating alternative splicing mechanisms for diseases.

Main Methods:

  • Literature review of studies on Bcl-2 family alternative splicing.
  • Analysis of the role of alternative splicing in protein function and disease.

Main Results:

  • Alternative splicing generates diverse Bcl-2 family isoforms, impacting apoptotic regulation.
  • Dysregulation of Bcl-2 protein balance due to altered splicing contributes to cancer and neurodegenerative diseases.
  • Restoring proper protein levels via splicing modulation is a promising therapeutic strategy.

Conclusions:

  • Alternative splicing significantly diversifies Bcl-2 family proteins, influencing cell fate.
  • Targeting alternative splicing mechanisms presents a potential therapeutic avenue for diseases linked to apoptosis dysregulation.

More Related Videos

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

Using the E1A Minigene Tool to Study mRNA Splicing Changes10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...